Evidence map›Paper›PMID 28841906›Full record

ArticleStem cell research & therapy2017

Term amniotic fluid: an unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications.

Roksana Moraghebi, Agnete Kirkeby, Patricia Chaves, Roger E Rönn, Ewa Sitnicka, Malin Parmar, Marcus Larsson, Andreas Herbst, Niels-Bjarne Woods

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Differentiation of CD117Pakistan journal of medical sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Roksana MoraghebiSection of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, BMC A12, 221 84, Lund, Sweden.
Agnete KirkebyWallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, BMC A11, 221 84, Lund, Sweden.
Patricia ChavesDepartment of Molecular Hematology, Lund Stem Cell Center, Lund University, BMC B12, 221 84, Lund, Sweden.
Roger E RönnSection of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, BMC A12, 221 84, Lund, Sweden.
Ewa SitnickaDepartment of Molecular Hematology, Lund Stem Cell Center, Lund University, BMC B12, 221 84, Lund, Sweden.
Malin ParmarWallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, BMC A11, 221 84, Lund, Sweden.
Marcus LarssonSkåne University Hospital, Department of Obstetrics, Lund University, Lund, Sweden. Marcus.Larsson@med.lu.se.
Andreas HerbstSkåne University Hospital, Department of Obstetrics, Lund University, Lund, Sweden. Andreas.Herbst@med.lu.se.
Niels-Bjarne WoodsSection of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, BMC A12, 221 84, Lund, Sweden. Niels-Bjarne.Woods@med.lu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clinical and clinical cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modelling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low volumes of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming.

methodsAmniotic fluid was collected at term caesarean section deliveries using a closed catheter-based system. Following fluid processing, amniotic fluid was assessed for cellularity, MSC frequency, in-vitro proliferation, surface phenotype, differentiation, and gene expression characteristics. Cells were also reprogrammed to the pluripotent stem cell state and differentiated towards neural and haematopoietic lineages.

resultsThe average volume of term amniotic fluid collected was approximately 0.4 litres per donor, containing an average of 7 million viable mononuclear cells per litre, and a CFU-F content of 15 per 100,000 MNCs. Expanded CFU-F cultures showed similar surface phenotype, differentiation potential, and gene expression characteristics to MSCs isolated from traditional sources, and showed extensive expansion potential and rapid doubling times. Given the high proliferation rates of these neonatal source cells, we assessed them in a reprogramming application, where the derived induced pluripotent stem cells showed multigerm layer lineage differentiation potential.

conclusionsThe potentially large donor base from caesarean section deliveries, the high yield of term amniotic fluid MSCs obtainable, the properties of the MSCs identified, and the suitability of the cells to be reprogrammed into the pluripotent state demonstrated these cells to be a promising and plentiful resource for further evaluation in bio-banking, cell therapy, disease modelling, and regenerative medicine applications.

Indexed as

Cell- and Tissue-Based TherapyCellular ReprogrammingAdipogenesisAmniotic FluidCell AdhesionCell DifferentiationCell LineCell LineageCell ProliferationCell SeparationEpithelial CellsFemaleFibroblastsHematopoiesisHumansInfant, NewbornBiobankingCaesarean section deliveriesCell-based therapyCellular reprogrammingMesenchymal stromal cellsPluripotencyRegenerative medicineTerm amniotic fluid

Identifiers

PMID28841906
PMCPMC5574087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.